Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.36 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.35 |
| ▸ | TUBB | P07437 | 1/20 | 0.35 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.35 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.35 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.35 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.35 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.35 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL221588 | 1.00 | NFE2L2 (0.42) | NFE2L2CA12CA1CA2CA7 | |
| Chlorotriphenylmethane SCHEMBL27667603 | 0.98 | NFE2L2 (0.41) | NFE2L2CA12CA1CA2CA7 | |
| Pyridine SCHEMBL6531371 | 0.91 | KDM4E (0.40) | NFE2L2SMN1; SMN2KCNA5TSHRNPC1 | |
| SCHEMBL2445301 | 0.86 | SMN1; SMN2 (0.39) | NFE2L2CA12CA1CA2CA7 | |
| SCHEMBL221217 | 0.85 | CA1 (0.46) | NFE2L2CA12CA1CA2CA7 | |
| SCHEMBL16675115 | 0.82 | NFE2L2 (0.45) | NFE2L2CA12CA1CA2CA7 | |
| SCHEMBL221587 | 0.82 | CA1 (0.46) | NFE2L2CA12CA1CA2CA7 | |
| SCHEMBL9013823 | 0.81 | NFE2L2 (0.44) | NFE2L2CA12CA1CA2CA7 | |
| SCHEMBL31430103 | 0.81 | NFE2L2 (0.44) | NFE2L2CA12CA1CA2CA7 | |
| SCHEMBL136230 | 0.81 | NFE2L2 (0.44) | NFE2L2CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119350413-A | Compound crystal form and preparation method and application thereof | 天津全和诚科技有限责任公司 | 2025-01-24 | — | — | CN | claimed |
| CN-119350415-A | Compound crystal form and preparation method and application thereof | 天津全和诚科技有限责任公司 | 2025-01-24 | — | — | CN | claimed |
| CN-119350412-A | Compound crystal form and preparation method and application thereof | 天津全和诚科技有限责任公司 | 2025-01-24 | — | — | CN | claimed |
| CN-119350414-A | Compound crystal form and preparation method and application thereof | 天津全和诚科技有限责任公司 | 2025-01-24 | — | — | CN | claimed |
| US-20260009029-A1 | COMPOUND FOR INHIBITING EXPRESSION OF LPA GENE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | RIGERNA THERAPEUTICS SUZHOU CO LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| CN-119350137-A | Method for purifying 1-methoxy-2-propanol through selective covalent reaction | 厦门大学 | 2025-01-24 | — | — | CN | disclosed |
| CN-119350413-A | Compound crystal form and preparation method and application thereof | 天津全和诚科技有限责任公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-119350415-A | Compound crystal form and preparation method and application thereof | 天津全和诚科技有限责任公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-119350414-A | Compound crystal form and preparation method and application thereof | 天津全和诚科技有限责任公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-119350412-A | Compound crystal form and preparation method and application thereof | 天津全和诚科技有限责任公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-113549121-B | Preparation method of nucleoside modifier | 上海兆维科技发展有限公司 | 2023-05-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260009029-A1 | COMPOUND FOR INHIBITING EXPRESSION OF LPA GENE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | LPAR6, LPAR2, LPAR1 | NFE2L2 2798/4885CA12 3621/4885CA1 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.